← Back to All US Stocks

Translational Development Acquisition Corp. (TDACW) Stock Fundamental Analysis & AI Rating 2026

TDACW Nasdaq Blank Checks CIK: 0001926599
Recently Updated • Analysis: Apr 17, 2026 • SEC Data: 2025-12-31
STRONG SELL
88% Conf
Pending
Analysis scheduled

📊 TDACW Key Takeaways

Revenue: N/A
Net Margin: N/A
Free Cash Flow: $-608.4K
Current Ratio: 0.07x
Debt/Equity: N/A
EPS: $0.00
AI Rating: STRONG SELL with 88% confidence
Translational Development Acquisition Corp. (TDACW) receives a STRONG SELL rating with 88% confidence from our AI fundamental analysis based on SEC 10-K filings. Below is our complete TDACW stock analysis for 2026.

Is Translational Development Acquisition Corp. (TDACW) a Good Investment?

Claude

TDACW exhibits critical financial distress with negative stockholders equity (-$6.5M) and a severe liquidity crisis (0.07x current ratio with only $29.8K available cash against $6.6M liabilities). As a blank-check company pre-business combination, the company faces existential risks around meeting near-term obligations and achieving a successful SPAC merger before capital depletion.

Why Buy Translational Development Acquisition Corp. Stock? TDACW Key Strengths

Claude
  • + Substantial gross asset base of $181.7M held in trust structure
  • + Relatively modest absolute liability burden at $6.6M
  • + Positive net income of $6.4M from non-operating sources

TDACW Stock Risks: Translational Development Acquisition Corp. Investment Risks

Claude
  • ! Negative stockholders equity indicates technical insolvency and breach of debt covenants
  • ! Critically inadequate liquidity with $29.8K cash against immediate obligations
  • ! Negative operating cash flow of -$608.4K demonstrating ongoing capital burn
  • ! No operational revenue or business model as pre-combination SPAC
  • ! Zero insider Form 4 activity signals lack of management confidence
  • ! Imminent risk of redemption cascade, merger deadline failure, or forced liquidation

Key Metrics to Watch

Claude
  • * Path to positive stockholders equity and covenant compliance
  • * Monthly cash burn rate and runway until capital exhaustion
  • * SPAC business combination status and shareholder redemption levels

Translational Development Acquisition Corp. (TDACW) Financial Metrics & Key Ratios

Revenue
N/A
Net Income
$6.4M
EPS (Diluted)
$0.00
Free Cash Flow
$-608.4K
Total Assets
$181.7M
Cash Position
$29.8K

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

TDACW Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA 3.5%
FCF Margin N/A

TDACW vs Market Sector: How Translational Development Acquisition Corp. Compares

How Translational Development Acquisition Corp. compares to Market sector averages

Net Margin
TDACW 0.0%
vs
Sector Avg 12.0%
TDACW Sector
ROE
TDACW 0.0%
vs
Sector Avg 15.0%
TDACW Sector
Current Ratio
TDACW 0.1x
vs
Sector Avg 1.8x
TDACW Sector
Debt/Equity
TDACW 0.0x
vs
Sector Avg 0.7x
TDACW Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Translational Development Acquisition Corp. Stock Overvalued? TDACW Valuation Analysis 2026

Based on fundamental analysis, Translational Development Acquisition Corp. has mixed fundamental signals relative to the Market sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.7x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Translational Development Acquisition Corp. Balance Sheet: TDACW Debt, Cash & Liquidity

Current Ratio
0.07x
Quick Ratio
0.07x
Debt/Equity
N/A
Debt/Assets
3.6%
Interest Coverage
N/A
Long-term Debt
N/A

TDACW Revenue & Earnings Growth: 5-Year Financial Trend

TDACW 5-year financial data:
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Translational Development Acquisition Corp.'s revenue has remained relatively flat over the 5-year period, with a 0% decline.

TDACW Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

Translational Development Acquisition Corp. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$608.4K
Cash generated from operations
Dividends
None
No dividend program

TDACW SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Translational Development Acquisition Corp. (CIK: 0001926599)

📋 Recent SEC Filings

Date Form Document Action
Mar 30, 2026 10-K tdac-20251231x10k.htm View →
Nov 14, 2025 10-Q tdac-20250930x10q.htm View →
Aug 14, 2025 8-K tm2523311d1_8k.htm View →
Aug 14, 2025 10-Q tdac-20250630x10q.htm View →
May 15, 2025 10-Q tdac-20250331x10q.htm View →

Frequently Asked Questions about TDACW

What is the AI rating for TDACW?

Translational Development Acquisition Corp. (TDACW) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.

What are TDACW's key strengths?

Claude: Substantial gross asset base of $181.7M held in trust structure. Relatively modest absolute liability burden at $6.6M.

What are the risks of investing in TDACW?

Claude: Negative stockholders equity indicates technical insolvency and breach of debt covenants. Critically inadequate liquidity with $29.8K cash against immediate obligations.

What is TDACW's revenue and growth?

Translational Development Acquisition Corp. reported revenue of N/A.

Does TDACW pay dividends?

Translational Development Acquisition Corp. does not currently pay dividends.

Where can I find TDACW SEC filings?

Official SEC filings for Translational Development Acquisition Corp. (CIK: 0001926599) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is TDACW's EPS?

Translational Development Acquisition Corp. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is TDACW a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Translational Development Acquisition Corp. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is TDACW stock overvalued or undervalued?

Valuation metrics for TDACW: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy TDACW stock in 2026?

Our dual AI analysis gives Translational Development Acquisition Corp. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is TDACW's free cash flow?

Translational Development Acquisition Corp.'s operating cash flow is $-608.4K, with capital expenditures of N/A.

How does TDACW compare to other Market stocks?

Vs Default sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.07 (avg: 1.8).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 17, 2026 | Data as of: 2025-12-31 | Powered by Claude AI